Trade ALPS Medical Breakthroughs ETF - SBIO CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.29
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02221 %(-$1.11)Trade size with leverage ~ $5,000.00Money from leverage ~ $$4,000.00Go to platform: -0.02221%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.00002 %(-$0.00)Trade size with leverage ~ $5,000.00Money from leverage ~ $$4,000.00Go to platform: -0.00002%
• Overnight funding adjustment time: 22:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02221 %
  (-$1.11)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.00002 %
  (-$0.00)

Key Stats

• Prev. Close: 57.36
• Open: 57.12
• 1-Year Change: 29.14%
• Day's Range: 57.12 - 58.14

Trade ALPS Medical Breakthroughs ETF - SBIO

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.